What is SimBioSys?
SimBioSys, an acronym for Simulated Biological Systems, is at the forefront of oncology innovation. The company has developed a sophisticated simulation engine, TumorScope, which transforms standard diagnostic data, including imaging and pathology, into detailed, spatially resolved virtual models of individual tumors and their microenvironments. By integrating mechanistic models that account for key cancer hallmarks such as drug sensitivity, delivery, metabolism, and mechanical forces, TumorScope offers precise predictions of therapy response and critical insights into resistance mechanisms. This approach complements and potentially surpasses existing precision medicine techniques by relying on readily available datasets, thereby empowering healthcare professionals and patients with enhanced disease understanding and the ability to computationally assess all treatment options for true personalization.
How much funding has SimBioSys raised?
SimBioSys has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2021): $15M with participation from Genoa Ventures, AV8 Ventures, Northpond Ventures, Mayo Clinic, and Heritage Medical Group
Key Investors in SimBioSys
Genoa Ventures
Genoa Ventures is an investment firm focused on early-stage companies at the intersection of biology and technology, aiming to empower category-defining ventures that can transform industries and foster a healthier world.
AV8 Ventures
AV8 Ventures supports early-stage startups in sectors like healthcare, enterprise, and deep-tech, partnering with founders to build category-defining companies with a long-term commitment.
Northpond Ventures
Northpond Ventures is an investment firm that focuses on companies operating in the life sciences and technology sectors, aiming to support innovation and growth in these critical industries.
What's next for SimBioSys?
With its recent major strategic investment, SimBioSys is poised for significant expansion and further development of its TumorScope platform. The company's focus on virtualizing cancer and providing individualized treatment insights positions it as a key player in the evolving landscape of precision oncology. Future growth is likely to involve deeper integration into clinical workflows, broader adoption by research institutions, and continued refinement of its AI and simulation capabilities to address complex cancer pathologies and drug resistance. The substantial enterprise-level backing signals strong market confidence in SimBioSys's disruptive technology and its potential to set new standards of care in cancer treatment.
See full SimBioSys company page
